Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $78.55, while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ROBO | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $6.79 |
52-Week Low | $63.04 | $2.84 |
Market Cap | — | $1.86B |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.65, down 1.14% with a bearish technical signal. The robotics ETF faces mixed momentum as moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with NVIDIA's AI growth outlook providing sector tailwinds.
The ETF offers diversified exposure to robotics growth themes, though valuation metrics are unavailable. Key risks include sector concentration and AI adoption pace variability. Analyst sentiment appears cautiously optimistic given the structural growth drivers in industrial automation and physical AI applications.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
